Chlamydia trachomatis vaccine development – a view on the current challenges and how to move forward. (2nd November 2022)

• Record Type: Journal Article
• Authors: Borges, Álvaro H.; Follmann, Frank; Dietrich, Jes
• Is Part Of: Expert review of vaccines. Volume 21:Number 11(2022)
• Page Start: 1555
• Page End: 1567
• Publication Date: 2022-11-02
• Subjects: Chlamydia -- vaccines -- T cells -- infection -- immunology; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2022.2117694
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction: Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the world. A licensed vaccine is not yet available, but the first vaccines have entered clinical trials. Areas covered: We describe the progress that has been made in our understanding of the type of immunity that a protective vaccine should induce, and the challenges that vaccine developers face. We also focus on the clinical development of a chlamydia vaccine. The first chlamydia vaccine candidate has now been tested in a clinical phase I trial, and another phase I trial is currently running. We discuss what it will take to continue this development and what future trial setups could look like. Expert opinion: The chlamydia field is coming of age and the first phase I clinical trial of a C. trachomatis vaccine has been successfully completed. We expect and hope that this will motivate various stakeholders to support further development of chlamydia vaccines in humans.